Twelve patients with NPM1 mutations were identified, although they did not harbor FLT3-ITD mutations that have been associated with favorable prognoses in AML[13]; 1 of these 12 patients had a concomitant FLT3 tyrosine kinase domain mutation, which has been associated with good prognosis.[14] One patient had a CEBPA mutation (confirmed by both NGS and Sanger sequencing) that has been associated with favorable outcomes.[15]. This evidence concerns the gene CEBPA and acute myeloid leukemia.